Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: A population pharmacokinetic analysis

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 5, 2011, Pages 614-624

  Shi, X J ^a   Geng, F ^a   Jiao, Z ^a   Cui, X Y ^a   Qiu, X Y ^a   Zhong, M K ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

ABCB1; CYP3A4*18B; CYP3A5*3; population pharmacokinetics; tacrolimus

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; TACROLIMUS;

ABCB1 GENE; ADULT; CHINESE; CYP3A4 GENE; CYP3A5 GENE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; REVIEW; TANDEM MASS SPECTROMETRY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; TACROLIMUS; YOUNG ADULT;

EID: 80052851361     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01206.x     Document Type: Review

References (53)

1. Kelly PA, Burckart GJ, Venkataramanan R, (1995) Tacrolimus: a new immunosuppressive agent. American Journal of Health-System Pharmacy, 52, 1521-1535.
2. Venkataramanan R, Swaminathan A, Prasad T, et al. (1995) Clinical pharmacokinetics of tacrolimus. Clinical Pharmacokinetics, 29, 404-430. (Pubitemid 26004179)
3. Anglicheau D, Legendre C, Beaune P, Thervet E, (2007) Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics, 8, 835-849. (Pubitemid 47288980)
4. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, Wojnowski L, (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clinical Chemistry, 51, 1374-1381. (Pubitemid 41060869)
5. Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A, (2008) Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplantation Proceedings, 40, 1690-1695. (Pubitemid 351853194)
6. Hu YF, Tu JH, Tan ZR, et al. (2007) Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica, 37, 315-327.
7. Fukushima-Uesaka H, Saito Y, Watanabe H, et al. (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Human Mutation, 23, 100.
8. Qiu XY, Jiao Z, Zhang M, et al. (2008) Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. European Journal of Clinical Pharmacology, 64, 1069-1084.
9. Hu Y-F, He J, Chen G-L, et al. (2005) CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clinica Chimica Acta; International Journal of Clinical Chemistry, 353, 187-192. (Pubitemid 40215445)
10. Saeki M, Saito Y, Nakamura T, et al. (2003) Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Human Mutation, 21, 653.
11. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J, (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and 6, in a Japanese population. Pharmacogenetics, 12, 331-334. (Pubitemid 34620661)
12. Jun KR, Lee W, Jang MS, et al. (2009) Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation, 87, 1225-1231.
13. Choi JH, Lee YJ, Jang SB, Lee J-E, Kim KH, Park K, (2007) Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. British Journal of Clinical Pharmacology, 64, 185-191. (Pubitemid 47063248)
14. Kuehl P, Zhang J, Lin Y, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 27, 383-391. (Pubitemid 32268418)
15. Hu YF, Qiu W, Liu ZQ, et al. (2006) Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clinical and Experimental Pharmacology and Physiology, 33, 1093-1098. (Pubitemid 44581573)
16. Zeng Y, He YJ, He FY, Fan L, Zhou HH, (2009) Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacologica Sinica, 30, 478-484.
17. Schwab M, Eichelbaum M, Fromm MF, (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annual Review of Pharmacology and Toxicology, 43, 285-307. (Pubitemid 37372643)
18. Hall SD, Thummel KE, Watkins PB, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metabolism and Disposition, 27, 161-166. (Pubitemid 29072066)
19. Kim RB, Leake BF, Choo EF, et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clinical Pharmacology and Therapeutics, 70, 189-199. (Pubitemid 32777772)
20. Marzolini C, Paus E, Buclin T, Kim RB, (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics, 75, 13-33. (Pubitemid 38130115)
21. Sakaeda T, Nakamura T, Okumura K, (2004) Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Current Topics in Medicinal Chemistry, 4, 1385-1398. (Pubitemid 39242880)
22. Zheng H, Webber S, Zeevi A, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. American Journal of Transplantation, 3, 477-483. (Pubitemid 36560101)
23. Wang W, Zhang XD, Ma LL, et al. (2005) Relationship between MDR1 gene polymorphism and blood concentration of tacrolimus in renal transplant patients. Zhonghua Yi Xue Za Zhi, 85, 3277-3281. (Pubitemid 43173660)
24. Macphee IAM, Fredericks S, Tai T, et al. (2002) Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation, 74, 1486-1489. (Pubitemid 36014218)
25. Li D, Gui R, Li J, Huang Z, Nie X, (2006) Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplantation Proceedings, 38, 2850-2852. (Pubitemid 44737980)
26. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. Journal of the American Society of Nephrology, 14, 1889-1896. (Pubitemid 36750485)
27. Op den Buijsch RA, Christiaans MH, Stolk LM, et al. (2007) Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundamental and Clinical Pharmacology, 21, 427-435. (Pubitemid 47084029)
28. Haufroid V, Mourad M, Van Kerckhove V, et al. (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics, 14, 147-154. (Pubitemid 38373108)
29. Tsuchiya N, Satoh S, Tada H, et al. (2004) Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 78, 1182-1187. (Pubitemid 39426437)
30. Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL, (2007) Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. Journal of Clinical Pharmacy and Therapeutics, 32, 505-515. (Pubitemid 47404287)
31. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS, (2005) Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clinical Transplantation, 19, 638-643. (Pubitemid 41341696)
32. Garrigues TM, Martin U, Peris-Ribera JE, Prescott LF, (1991) Dose-dependent absorption and elimination of cefadroxil in man. European Journal of Clinical Pharmacology, 41, 179-183.
33. Holford NH, Ambros RJ, Stoeckel K, (1992) Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. Journal of Pharmacokinetics and Biopharmaceutics, 20, 421-442. (Pubitemid 23034408)
34. Matis JH, Wehrly TE, Ellis WC, (1989) Some generalized stochastic compartment models for digesta flow. Biometrics, 45, 703-720.
35. Hartmann D, Gysel D, Dubach UC, Forgo I, (1990) Pharmacokinetic modelling of the plasma concentration-time profile of the vitamin retinyl palmitate following intramuscular administration. Biopharmaceutics and Drug Disposition, 11, 689-700. (Pubitemid 20372070)
36. Comets E, Mentre F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J, (2000) Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. Journal of Pharmaceutical Sciences, 89, 1123-1133.
37. Rousseau A, Leger F, Le Meur Y, Saint-Marcoux F, Paintaud G, Buchler M, Marquet P, (2004) Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Therapeutic Drug Monitoring, 26, 23-30. (Pubitemid 38140906)
38. Mandema JW, Verotta D, Sheiner LB, (1992) Building population pharmacokinetic - pharmacodynamic models. I. Models for covariate effects. Journal of Pharmacokinetics and Biopharmaceutics, 20, 511-528. (Pubitemid 23034413)
39. Hooker AC, Staatz CE, Karlsson MO, (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharmaceutical Research, 24, 2187-2197. (Pubitemid 350060706)
40. Robert J B, (2009) NONMEM users guide: introduction to NONMEM 7. Ellicott City, MD: ICON Development Solutions.
41. Efron B, Gong G, (1983) A leisurely look at the bootstrap, the jackknife, and cross-validation. American Statistician, 37, 36-48.
42. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV, (2003) Model appropriateness and population pharmacokinetic modeling. Journal of Clinical Pharmacology, 43, 610-623. (Pubitemid 36613120)
43. Yano Y, Beal SL, Sheiner LB, (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. Journal of Pharmacokinetics and Pharmacodynamics, 28, 171-192.
44. Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY, (2007) Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. Journal of Clinical Pharmacy and Therapeutics, 32, 89-95. (Pubitemid 46213944)
45. Fukudo M, Yano I, Masuda S, et al. (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clinical Pharmacology and Therapeutics, 80, 331-345. (Pubitemid 44479749)
46. Press RR, Ploeger BA, den Hartigh J, et al. (2009) Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Therapeutic Drug Monitoring, 31, 187-197.
47. Wang J, (2009) CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Review of Molecular Diagnostics, 9, 383-390.
48. Renders L, Frisman M, Ufer M, et al. (2007) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clinical Pharmacology and Therapeutics, 81, 228-234. (Pubitemid 46174820)
49. Zheng H, Zeevi A, Schuetz E, et al. (2004) Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. Journal of Clinical Pharmacology, 44, 135-140. (Pubitemid 38114311)
50. Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y, (2008) Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. British Journal of Clinical Pharmacology, 66, 154-155. (Pubitemid 351822158)
51. Evans WE, McLeod HL, (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. New England Journal of Medicine, 348, 538-549. (Pubitemid 36159890)
52. Sakaeda T, (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metabolism and Pharmacokinetics, 20, 391-414.
53. Burckart GJ, Liu XI, (2006) Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Therapeutic Drug Monitoring, 28, 23-30. (Pubitemid 44391689)